Table 2. Clinical, laboratory and... | American Society of Hematology

Table 2.

Clinical, laboratory and molecular characteristics of patients with MPL515 mutations (at the time of MPL515 testing)

Patient no.	Sex/age, y, at diagnosis	Diagnosis	JAK2V617F status	MPL515 status	MPL515 mutant peak/wild-type peak ratio, %	Cytogenetics	Hgb, g/dL	WBC count, × 10⁹/L	Platelet count, × 10⁹/L	AML	Status at last follow-up	Duration of follow-up, mo
Mayo study
1	M/32	De novo MMM	WT	W515L	< 50	Normal	11.4	5.5	436	No	Alive	40
2	M/46	De novo MMM	Heterozygous	W515L	< 50	del(13q)	9.5	5.3	379	No	Deceased	91
3	M/64	De novo MMM	WT	W515L	< 50	del(20q)	9.9	5.7	182	No	Alive	94
4	M/60	De novo MMM	WT	W515K	< 50	Normal	8.3	4.5	215	No	Alive	30
5	M/61	De novo MMM	WT	W515L	< 50	ND	11.5	36.6	139	No	Alive	22
6	M/75	Post-de novo MMM AML (M0)	WT	W515L	> 50	t(1;7) t(1;21)^*	9.0	72.1	161	n/a	Deceased	34
7	F/52	Post-de novo MMM AML (M2)	WT	W515K	100	Normal	9.0	10.6	430	n/a	Alive	67
8	M/49	De novo MMM	Heterozygous	W515L + W515K	< 50	Normal	8.2	4.6	40	No	Alive	23
9	F/53	De novo MMM	Heterozygous	W515L + W515K	< 50	Complex abnormalities	6.3	8.5	124	Yes	Deceased	20
10	M/58	De novo MMM	WT	W515K	100	del(11q)^*	11.5	10.3	146	No	Alive	108
11	M/71	ET	WT	W515L	< 50	Normal	14.0	6.9	959	No	Alive	168
12	F/67	ET	WT	W515L	> 50	t(1;21)	9.1	4.1	1539	Yes	Deceased	172
13	M/81	Post-ET MMM AML (M2)	WT	W515L	100	t(8;21)	9.6	47.4	161	n/a	Deceased	72
Harvard study
14	F/59	De novo MMM	WT	W515L	NA	Normal	NA	NA	NA	No	Alive	NA
15	F/5	De novo MMM	WT	W515L	NA	Normal	9.4	7.5	261	No	Alive	NA
16	M/58	De novo MMM	WT	W515L	NA	del(16q)^*	10.8	7.2	120	Yes	Deceased	36
17	F/68	De novo MMM	WT	W515L	NA	Normal	10.1	17.7	559	No	Alive	96
18	F/45	ET	Heterozygous	W515L	NA	Normal	NA	NA	NA	No	Alive	24
19	F/56	ET	Heterozygous	W515L	NA	Normal	NA	NA	658	No	Alive	168
20	F/67	Post-ET MMM	Heterozygous	W515L	NA	Normal	NA	NA	650	No	Alive	NA

Patient no.	Sex/age, y, at diagnosis	Diagnosis	JAK2V617F status	MPL515 status	MPL515 mutant peak/wild-type peak ratio, %	Cytogenetics	Hgb, g/dL	WBC count, × 10⁹/L	Platelet count, × 10⁹/L	AML	Status at last follow-up	Duration of follow-up, mo
Mayo study
1	M/32	De novo MMM	WT	W515L	< 50	Normal	11.4	5.5	436	No	Alive	40
2	M/46	De novo MMM	Heterozygous	W515L	< 50	del(13q)	9.5	5.3	379	No	Deceased	91
3	M/64	De novo MMM	WT	W515L	< 50	del(20q)	9.9	5.7	182	No	Alive	94
4	M/60	De novo MMM	WT	W515K	< 50	Normal	8.3	4.5	215	No	Alive	30
5	M/61	De novo MMM	WT	W515L	< 50	ND	11.5	36.6	139	No	Alive	22
6	M/75	Post-de novo MMM AML (M0)	WT	W515L	> 50	t(1;7) t(1;21)^*	9.0	72.1	161	n/a	Deceased	34
7	F/52	Post-de novo MMM AML (M2)	WT	W515K	100	Normal	9.0	10.6	430	n/a	Alive	67
8	M/49	De novo MMM	Heterozygous	W515L + W515K	< 50	Normal	8.2	4.6	40	No	Alive	23
9	F/53	De novo MMM	Heterozygous	W515L + W515K	< 50	Complex abnormalities	6.3	8.5	124	Yes	Deceased	20
10	M/58	De novo MMM	WT	W515K	100	del(11q)^*	11.5	10.3	146	No	Alive	108
11	M/71	ET	WT	W515L	< 50	Normal	14.0	6.9	959	No	Alive	168
12	F/67	ET	WT	W515L	> 50	t(1;21)	9.1	4.1	1539	Yes	Deceased	172
13	M/81	Post-ET MMM AML (M2)	WT	W515L	100	t(8;21)	9.6	47.4	161	n/a	Deceased	72
Harvard study
14	F/59	De novo MMM	WT	W515L	NA	Normal	NA	NA	NA	No	Alive	NA
15	F/5	De novo MMM	WT	W515L	NA	Normal	9.4	7.5	261	No	Alive	NA
16	M/58	De novo MMM	WT	W515L	NA	del(16q)^*	10.8	7.2	120	Yes	Deceased	36
17	F/68	De novo MMM	WT	W515L	NA	Normal	10.1	17.7	559	No	Alive	96
18	F/45	ET	Heterozygous	W515L	NA	Normal	NA	NA	NA	No	Alive	24
19	F/56	ET	Heterozygous	W515L	NA	Normal	NA	NA	658	No	Alive	168
20	F/67	Post-ET MMM	Heterozygous	W515L	NA	Normal	NA	NA	650	No	Alive	NA

MPL515 mutant peak/wild-type peak ratio was the ratio on sequencing chromatogram × 100. MMM indicates myelofibrosis with myeloid metaplasia; ET, essential thrombocythemia; AML, acute myeloid leukemia; WT, wild type; Hgb, hemoglobin; n/a, not applicable; NA, not available; and ND, not done

Cytogenetic abnormalities developed after identification of MPL515 mutations

View Large

This Feature Is Available To Subscribers Only